ReviewOncoTargets and therapy2018
Drug response to PD-1/PD-L1 blockade: based on biomarkers.
Review in OncoTargets and therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- PolyoxidoniumFrontiers in immunology · 2019Trial
- Emerging biomarkers for early cancer detection and diagnosis: challenges, innovations, and clinical perspectives.European journal of medical research · 2025Review
- Article
- Biomarkers and computational models for predicting efficacy to tumor ICI immunotherapy.Frontiers in immunology · 2024Review
- Article
- Monalizumab efficacy correlates with HLA-E surface expression and NK cell activity in head and neck squamous carcinoma cell lines.Journal of cancer research and clinical oncology · 2023Article
- Immunotherapy in non-small cell lung cancer: Past, present, and future directions.Frontiers in oncology · 2022Review
- B7-H4 is increased in lung adenocarcinoma harboring EGFR-activating mutations and contributes to immunosuppression.Oncogene · 2022Article
- Predictive molecular markers for the treatment with immune checkpoint inhibitors in colorectal cancer.Journal of clinical laboratory analysis · 2022Review
- DNA5mC Regulator-Mediated Molecular Clusters and Tumor Microenvironment Signatures in Glioblastoma.Frontiers in cell and developmental biology · 2022Article
- The landscape of copy number variations in classical Hodgkin lymphoma: a joint KU Leuven and LYSA study on cell-free DNA.Blood advances · 2021Article
- Predictive value of tumor mutation burden (TMB) with targeted next-generation sequencing in immunocheckpoint inhibitors for non-small cell lung cancer (NSCLC).Journal of Cancer · 2021Article
- Extracellular Vesicles and Their Roles in Cancer Progression.Methods in molecular biology (Clifton, N.J.) · 2021Article
- From the T-cell receptor to cancer therapy: an interview with Tak W. Mak.Cell death and differentiation · 2021Article
- Surgery after neoadjuvant immunotherapy in patients with resectable non-small cell lung cancer.Translational lung cancer research · 2021Review
- Current and Future Perspectives of PD-1/PDL-1 Blockade in Cancer Immunotherapy.Journal of immunology research · 2021Review
- Potential Biomarkers for the Efficacy of PD-1-PD-L Blockade in Cancer.OncoTargets and therapy · 2021Review
- Nuclear imaging-guided PD-L1 blockade therapy increases effectiveness of cancer immunotherapy.Journal for immunotherapy of cancer · 2020Article
- In Cellulo Evaluation of the Therapeutic Potential of NHC Platinum Compounds in Metastatic Cutaneous Melanoma.International journal of molecular sciences · 2020Article
- Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines.Journal for immunotherapy of cancer · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, immunotherapies targeting programmed death-1 (PD-1)/programmed death ligand 1 (PD-L1) have provided great hopes for patients with cancer. A successful anti-PD-1/PD-L1 therapy includes not only the elimination of immunosuppressive tumor cells but also the rejuvenation of exhausted T cells. Nevertheless, the efficacy of therapy is still low, so that biomarker-driven therapy has attracted more and more attention to identify patients who are likely to benefit from therapy and to reduce unnecessary disease progression. While many studies have focused on characteristics of tumor biopsies, biomarkers linked to T cell exhaustion and rejuvenation have just become new hot spots in drug response studies. However, no biomarker is perfect in drug response prediction currently, so there is an urgent need for other biomarkers to compensate for the deficiency. In this review, we summarize some approved and candidate biomarkers predictive of drug response before and during PD-1/PD-L1 blockade, including those characterizing responsive or suppressive tumor cells and those evaluating the T cell rejuvenation. Overall, we set up a comprehensive network of biomarkers of tumor characteristics and T cell rejuvenation, predicting drug response before and during anti-PD-1/PD-L1 therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.